Jean-Luc Villeval was born in the Ardennes, France in 1954. He received a Ph.D. degree in endocrinology and development from Paris XII University in 1987 related to the novel characterization of early erythroid leukemia, called LAM6b. He obtained a postdoctoral training at the Walter and Eliza Hall Institute of Medical Research (WEHI), Cancer Research Unit, Melbourne, Australia, under the supervision of Professor D. Metcalf, on Epo retroviral gene transfer and blood stem cell mobilization after G-CSF and GM-CSF early clinical trials. He joined the INSERM, in the Molecular Genetics and Hematology Unit directed by Professor J. Rosa, Créteil, France in 1990. He moved with Dr. W. Vainchenker in 1992 to form the Hematopoiesis and Stem Cell INSERM Research Unit at the Institute Gustave Roussy (IGR), Villejuif, France where he presently works as a Director of research. In 1997, he worked as a Visiting Scientist at the Dana Farber Cancer Institute, Boston, MA, with R. Shivdasani on NFE2 and platelets. From 1997 to 2004, he joined the Biotherapeutics then Inflammation team at Millennium Pharmaceuticals Inc., Boston, MA, working with D. Gearing and JC Gutierrez on large-scale in vivo target gene validation including therapeutic utilities of platelet GPVI antagonists. His team is presently engaged in studies of normal and malignant hematopoiesis and has been particularly interested in myeloproliferative neoplasms (MPN), with the original characterization of the prevalent Jak2V617F mutation and associated preclinical studies. He is specialized in the development of in vivo disease models.
Biography Updated on 18 January 2011